Molecular Basis of PAC1R Allosteric Modulation with Lipids in Membranes

Overview

Journal bioRxiv

Date 2025 Feb 20

PMID 39974954

Authors

Nicholas B Hamilton

Bo Yang

Chijian Xiang

Tongtong Li

Severin T Schneebeli

Jianing Li

Affiliations

Soon will be listed here.

Abstract

The pituitary adenylate cyclase-activating polypeptide receptor I (PAC1R) represents a highly sought-after therapeutic target for chronic pain, migraine, and post-traumatic stress. As a class B G protein-coupled receptor (GPCR), the PAC1R is highly expressed throughout the neuronal and central nervous system membranes, with the receptor subject to hormone activation and subsequent signal transduction. Despite its desirable indication, small molecule agonists for PAC1R have been notoriously difficult to develop due to competition with PACAP. For this reason, allosteric activation of the receptor has emerged as a promising pathway. To probe potential allosteric sites, herein, we present a study of the receptor in biomimetic concentrations of lipid membranes. Our results reveal that cholesterol recognizes two canonical and two non-canonical binding sites at PAC1R, which may influence critical residues in the transmembrane domain and PAC1R activation. Also, our simulations suggest the glycolipid GM3 interacts with PAC1R in both the extracellular and transmembrane domains. These lipid binding hotspots may hold high potential for advancing our understanding of class B GPCR signaling and the discovery of new molecules targeting PAC1R.

References

Schwandt M, Cortes C, Kwako L, George D, Momenan R, Sinha R . The CRF1 Antagonist Verucerfont in Anxious Alcohol-Dependent Women: Translation of Neuroendocrine, But not of Anti-Craving Effects. Neuropsychopharmacology. 2016; 41(12):2818-2829. PMC: 5061889. DOI: 10.1038/npp.2016.61. View

Sejdiu B, Tieleman D . Lipid-Protein Interactions Are a Unique Property and Defining Feature of G Protein-Coupled Receptors. Biophys J. 2020; 118(8):1887-1900. PMC: 7175695. DOI: 10.1016/j.bpj.2020.03.008. View

Fala L . Tanzeum (Albiglutide): A Once-Weekly GLP-1 Receptor Agonist Subcutaneous Injection Approved for the Treatment of Patients with Type 2 Diabetes. Am Health Drug Benefits. 2015; 8(Spec Feature):126-30. PMC: 4665069. View

Zhao X, Liao C, Ma Y, Ferrell J, Schneebeli S, Li J . Top-down Multiscale Approach To Simulate Peptide Self-Assembly from Monomers. J Chem Theory Comput. 2019; 15(3):1514-1522. DOI: 10.1021/acs.jctc.8b01025. View

Geiger J, Sexton R, Al-Sahouri Z, Lee M, Chun E, Harikumar K . Evidence that specific interactions play a role in the cholesterol sensitivity of G protein-coupled receptors. Biochim Biophys Acta Biomembr. 2021; 1863(9):183557. PMC: 8656464. DOI: 10.1016/j.bbamem.2021.183557. View

Lomize M, Pogozheva I, Joo H, Mosberg H, Lomize A . OPM database and PPM web server: resources for positioning of proteins in membranes. Nucleic Acids Res. 2011; 40(Database issue):D370-6. PMC: 3245162. DOI: 10.1093/nar/gkr703. View

McKay K, Hamilton N, Remington J, Schneebeli S, Li J . Essential Dynamics Ensemble Docking for Structure-Based GPCR Drug Discovery. Front Mol Biosci. 2022; 9:879212. PMC: 9277106. DOI: 10.3389/fmolb.2022.879212. View

Tepper S, Cleves C . Telcagepant, a calcitonin gene-related peptide antagonist for the treatment of migraine. Curr Opin Investig Drugs. 2009; 10(7):711-20. View

Lu M, Zhao W, Han S, Lin X, Xu T, Tan Q . Activation of the human chemokine receptor CX3CR1 regulated by cholesterol. Sci Adv. 2022; 8(26):eabn8048. PMC: 9242592. DOI: 10.1126/sciadv.abn8048. View

10.

Wang J, Song X, Zhang D, Chen X, Li X, Sun Y . Cryo-EM structures of PAC1 receptor reveal ligand binding mechanism. Cell Res. 2020; 30(5):436-445. PMC: 7196072. DOI: 10.1038/s41422-020-0280-2. View

11.

Michaud-Agrawal N, Denning E, Woolf T, Beckstein O . MDAnalysis: a toolkit for the analysis of molecular dynamics simulations. J Comput Chem. 2011; 32(10):2319-27. PMC: 3144279. DOI: 10.1002/jcc.21787. View

12.

Lee J, Patel R, Lyman E . Ligand-dependent cholesterol interactions with the human A(2A) adenosine receptor. Chem Phys Lipids. 2013; 169:39-45. PMC: 3652319. DOI: 10.1016/j.chemphyslip.2013.02.002. View

13.

Thapa S, Clark F, Schneebeli S, Li J . Multiscale Simulations to Discover Self-Assembled Oligopeptides: A Benchmarking Study. J Chem Theory Comput. 2023; 20(1):375-384. PMC: 11070933. DOI: 10.1021/acs.jctc.3c00699. View

14.

Nishimura Y, Esaki T, Isshiki Y, Furuta Y, Mizutani A, Kotake T . Lead Optimization and Avoidance of Reactive Metabolite Leading to PCO371, a Potent, Selective, and Orally Available Human Parathyroid Hormone Receptor 1 (hPTHR1) Agonist. J Med Chem. 2020; 63(10):5089-5099. DOI: 10.1021/acs.jmedchem.9b01743. View

15.

Liao C, de Molliens M, Schneebeli S, Brewer M, Song G, Chatenet D . Targeting the PAC1 Receptor for Neurological and Metabolic Disorders. Curr Top Med Chem. 2019; 19(16):1399-1417. PMC: 6761004. DOI: 10.2174/1568026619666190709092647. View

16.

van Aalst E, Wylie B . Cholesterol Is a Dose-Dependent Positive Allosteric Modulator of CCR3 Ligand Affinity and G Protein Coupling. Front Mol Biosci. 2021; 8:724603. PMC: 8417553. DOI: 10.3389/fmolb.2021.724603. View

17.

Bond A . Exenatide (Byetta) as a novel treatment option for type 2 diabetes mellitus. Proc (Bayl Univ Med Cent). 2007; 19(3):281-4. PMC: 1484540. DOI: 10.1080/08998280.2006.11928181. View

18.

Alhadeff R, Vorobyov I, Yoon H, Warshel A . Exploring the free-energy landscape of GPCR activation. Proc Natl Acad Sci U S A. 2018; 115(41):10327-10332. PMC: 6187162. DOI: 10.1073/pnas.1810316115. View

19.

Shintani Y, Hayata-Takano A, Moriguchi K, Nakazawa T, Ago Y, Kasai A . β-Arrestin1 and 2 differentially regulate PACAP-induced PAC1 receptor signaling and trafficking. PLoS One. 2018; 13(5):e0196946. PMC: 5937772. DOI: 10.1371/journal.pone.0196946. View

20.

Liang Y, Belousoff M, Zhao P, Koole C, Fletcher M, Truong T . Toward a Structural Understanding of Class B GPCR Peptide Binding and Activation. Mol Cell. 2020; 77(3):656-668.e5. DOI: 10.1016/j.molcel.2020.01.012. View